| Company Name: |
Nanjing Paite Meisheng Technology Co., Ltd Gold
|
| Tel: |
15952038335 13327728092 |
| Email: |
xu_meiqin@petmedtech.com |
| Products Intro: |
Product Name:Cefovecin
CAS:234096-34-5
Purity:97.0% Package:5mg; 1g; 5g; 10g
|
|
| Product Name: | Cefovecin | | Synonyms: | Cefovecin;Convenia。;5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicacid,7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-8-oxo-3-[(2S)-tetrahydro-2-furanyl]-,(6R,7R)-;(7R)-7-{[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino}-8-oxo-3-[(2S)-tetrahydrofuran-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;(7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-3-[(2S)-oxolan-2-yl]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylicaci;Cephalosporin Impurity 11 (Cefovecin) | | CAS: | 234096-34-5 | | MF: | C17H19N5O6S2 | | MW: | 453.49 | | EINECS: | | | Product Categories: | | | Mol File: | 234096-34-5.mol |  |
| | Cefovecin Chemical Properties |
| density | 1.85±0.1 g/cm3(Predicted) | | pka | 2.78±0.50(Predicted) | | CAS DataBase Reference | 234096-34-5 |
| | Cefovecin Usage And Synthesis |
| Brand Name(s) in US | Convenia
| | Description | Cefovecin (brand name: Convenia®) is a cephalosporin antibiotic used most commonly for skin infections, periodontal disease, and urinary tract infections. It has also been used as a part of outpatient treatment for parvovirus and other bacterial infections. It is a long-acting injectable antibiotic and is therefore useful in cases when giving medications by mouth is difficult.
https://vcahospitals.com/know-your-pet/cefovecin | | Uses | Cefovecin is considered a third-generation cephalosporin but may not have the same activity as other injectable third-generation cephalosporins, such as cefotaxime.
Cefovecin is a new extended-spectrum semisynthetic cephalosporin indicated for the treatment of bacterial infections in dogs and cats. | | Uses | Cefovecin is a cephalosporin antibiotic used in the treatment of skin conditions in dogs and cats. | | Indications | Cefovecin is approved for use in dogs and cats. It is approved in the US for skin and soft tissue infections but also has been used to treat urinary tract infections, for which it is approved in some countries. The efficacy of cefovecin for treating infections in other sites, such as the respiratory tract, bone, and central nervous system, has not been established. Experience is limited to administration of cefovecin in dogs and Cats; the use in other species, such as horses, large animals, birds, and reptiles, is not recommended until specific dosing recommendations are published. | | Mode of action | Cephalosporin antibiotic. Action is similar to other beta-lactam antibiotics, which inhibit synthesis of bacterial cell wall leading to cell death. Cephalosporins are divided into first- , second , third-, and fourth -generation drugs depending on spectrum of activity. Cefovecin is considered a third -generation cephalosporin but may not have the same activity as other injectable third- generation cephalosporins, such as cefotaxime. Cefovecin has good activity against streptococci, Staplylococcus species, and gram-negative bacilli. MIC values are lower for cefovecin than first-generation cephalosporins. Some Enterobacterinceae can devlop resistance. It is not active against Psendomonas aernginosa. Methicillin resistant staphylococci are considered resistant to cefovecin. Activity against anaerobic bacteria is unpredictable. Cefovecin is greater than 99% protein bound in cats and greater than 98% in dogs, which is partly responsible for the long duration. The terminal half-life is approximately 7 days in cats and 5 days in dogs, and effective concentrations can be maintained in the tissue fluid of these species for 14 days. |
| | Cefovecin Preparation Products And Raw materials |
|